Nymox Pharmaceutical NX-1207 for BPH

On July 14, 2004 Nymox Pharmaceutical Corporation reported FDA approval for the NX-1207 clinical trial protocol for benign prostatic hyperplasia (BPH). In January 2004 the company had reported Phase I results which indicated that safety and tolerability data were sufficient for the company to move NX-1207 into Phase II testing. The recent FDA ruling has [...]

Visudyne

On January 29, 2004, U.S. health authorities expanded patient reimbursement for QLT’s Visudyne therapy to treat Wet Age Related Macular Degeneration (AMD). The changes, which could take effect by October 2004, will make 40,000 to 60,000 new patients eligible for reimbursement, potentially doubling QLT’s current patient pool of about 60,000. Until now, Medicaid has covered [...]